Navigation Links
Edwards Lifesciences to Present at the 18th Annual Wachovia Nantucket Equity Conference
Date:6/17/2008

IRVINE, Calif., June 17 /PRNewswire-FirstCall/ -- Edwards Lifesciences Corporation (NYSE: EW), a world leader in products and technologies to treat advanced cardiovascular disease, is scheduled to participate in the 18th Annual Wachovia Nantucket Equity Conference at the White Elephant Hotel in Nantucket, Massachusetts on Tuesday, June 24, 2008.

Thomas M. Abate, Edwards Lifesciences' corporate vice president, chief financial officer & treasurer, is scheduled to speak to conference attendees at 2:30 p.m. ET. A live webcast of the presentation will be available to all interested parties on the Edwards Lifesciences investor relations website at http://www.edwards.com/InvestorRelations/EventCalendar.htm. An archived version of the webcast will be available later that day on the Edwards investor relations website in the News and Events section.

About Edwards Lifesciences

Edwards Lifesciences is the global leader in the science of heart valves and hemodynamic monitoring. Headquartered in Irvine, Calif., Edwards treats advanced cardiovascular disease with its market-leading heart valve therapies, and critical care and vascular technologies. In 2008, Edwards celebrates 50 years of partnering with clinicians to develop life-saving innovations. The company's global brands, which are sold in approximately 100 countries, include CardioVations, the CardioVations logo, Carpentier-Edwards, Cosgrove- Edwards, FloTrac, Fogarty, PERIMOUNT Magna and Swan-Ganz. Additional company information can be found at http://www.edwards.com.

Edwards is a trademark of Edwards Lifesciences Corporation. Edwards Lifesciences, the stylized E logo, CardioVations, the CardioVations logo, Carpentier-Edwards, Cosgrove-Edwards, FloTrac, Fogarty, PERIMOUNT Magna and Swan-Ganz are trademarks of Edwards Lifesciences Corporation and are registered in the United States Patent and Trademark Office.


'/>"/>
SOURCE Edwards Lifesciences Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Edwards Lifesciences Opens New Singapore Heart Valve Facility
2. Edwards Lifesciences Celebrates One Million Heart Valve Patients and More at AATS 2008
3. Edwards Lifesciences to Webcast Annual Stockholders Meeting
4. Edwards Lifesciences Reports Strong First Quarter Results and Raises 2008 Guidance
5. Edwards Lifesciences Celebrates 50 Years of Life-Saving Innovations
6. Lambert, Edwards & Associates Named Agency of Record for The West Michigan Science & Technology Initiative
7. Edwards Lifesciences Announces First Human Implants of Next-Generation Transcatheter Heart Valve
8. Edwards Lifesciences Announces Organizational Changes
9. Edwards Lifesciences to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
10. Edwards Lifesciences to Host Earnings Conference Call on February 5, 2008
11. Edwards Lifesciences Receives FDA Approval to Add Transapical Delivery System to U.S. Clinical Trial of Transcatheter Heart Valve
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... , March 27, 2017  The global ... for 2016, according to a new report from ... lab testing is performed to evaluate disease progression, ... therapy, among other reasons.  The healthcare market research ... , provides an overview of the medical ...
(Date:3/27/2017)... ... March 27, 2017 , ... PMG Research is pleased to ... presented by The Conference Forum in Boston on April 3-4, 2017. The CTC conference ... clinical trial outcomes and bring them closer to the patient. Clinical Trial Collaborations also ...
(Date:3/27/2017)... -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital ... today announced that it is now offering a 3 ... who want to have their DarioHealth products reimbursed by ... agreements with partners across the U.S. who will be ... will supply and bill the customer,s insurance for their ...
(Date:3/24/2017)... MOSCOW and ROCKVILLE, Md. ... portfolio company of Maxwell Biotech Venture Fund (MBVF), today ... of SQ109 added to the standard drug therapy regimen ... a new small molecule drug discovered by scientists at ... US National Institutes of Health. A ...
Breaking Biology Technology:
(Date:3/2/2017)... -- Australian stem cell and regenerative medicine company, ... agreement with the Monash Lung Biology Network, a consortia ... Department of Pharmacology at Monash University, Melbourne ... support the use of Cymerus™ mesenchymal stem cells (MSCs) ... is a chronic, long term lung condition recognised by ...
(Date:2/28/2017)...  EyeLock LLC, ein marktführendes Unternehmen im Bereich ... Lösung zur Iris-Erkennung auf der neuesten Mobilplattform ... dem Mobile World Congress 2017 (27. Februar ... 3, Stand 3E10, vorstellen. Der ... – eine Kombination aus Hardware, Software und ...
(Date:2/22/2017)... LONDON , Feb. 22, 2017 ... by 2021, ABI Research identifies four technologies that ... solutions to secure significant share in the changing ... payments, and passive authentication.   "Companies ... it comes to security," says Dimitrios Pavlakis ...
Breaking Biology News(10 mins):